Diagnosis and treatment of hilar cholangiocarcinoma
10.3760/cma.j.cn115396-20220509-00163
- VernacularTitle:肝门部胆管癌的诊治进展
- Author:
Yuyang GUO
1
;
Xiangyu PENG
;
Lizhi LYU
;
Yi JIANG
;
Xinghua HUANG
;
Huanzhang HU
Author Information
1. 福建医科大学福总临床医学院，福州 350025
- Keywords:
Liver neoplasms;
Diagnosis;
Therapeutic uses;
Neoplasm staging;
Hilar cholangiocarcinoma
- From:
International Journal of Surgery
2022;49(8):553-558
- CountryChina
- Language:Chinese
-
Abstract:
Hilar cholangiocarcinoma(HCCA) is a hotpot and a difficult point in the field of hepatobiliary surgery. HCCA is the most common type of cholangiocarcinoma and is characterized by atypical early clinical manifestations, rapid progression and poor prognosis. There is no specific marker for HCCA and its preoperative diagnosis and evaluation mainly relies on imaging examination. Surgical treatment is still the main treatment, but most patients have lost the opportunity of surgical resection by the time of treatment. In recent years, a large number of studies have been conducted on the diagnosis and treatment of HCCA at home and abroad, and the efficacy of HCCA has been improved. Perioperative management, including the selection of preoperative drainage and perioperative chemoradiotherapy and others, improved postoperative survival. Among them, the application of preoperative radiotherapy and chemotherapy in the field of liver transplantation has achieved quite good results. Targeted therapy and immunotherapy have provided new treatment methods for HCCA. This paper reviews the diagnosis and multimodal treatment of HCCA.
